DE69427650T2 - Verbindungen mit wachstumshormon-freisetzenden eigenschaften - Google Patents

Verbindungen mit wachstumshormon-freisetzenden eigenschaften

Info

Publication number
DE69427650T2
DE69427650T2 DE69427650T DE69427650T DE69427650T2 DE 69427650 T2 DE69427650 T2 DE 69427650T2 DE 69427650 T DE69427650 T DE 69427650T DE 69427650 T DE69427650 T DE 69427650T DE 69427650 T2 DE69427650 T2 DE 69427650T2
Authority
DE
Germany
Prior art keywords
growth hormone
pct
hormone releasing
connections
date jun
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69427650T
Other languages
English (en)
Other versions
DE69427650D1 (de
Inventor
Nils Langeland Johansen
Jesper Lau
Kjeld Madsen
Behrend Friedrich Lundt
Henning Thogersen
Birgit Sehested Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helsinn Therapeutics US Inc
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK143893A external-priority patent/DK143893D0/da
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of DE69427650D1 publication Critical patent/DE69427650D1/de
Application granted granted Critical
Publication of DE69427650T2 publication Critical patent/DE69427650T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth-hormone releasing factors (GH-RF) (Somatoliberin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69427650T 1993-12-23 1994-12-22 Verbindungen mit wachstumshormon-freisetzenden eigenschaften Expired - Fee Related DE69427650T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK143893A DK143893D0 (de) 1993-12-23 1993-12-23
DK7594 1994-01-17
DK78194 1994-06-30
DK116594 1994-10-07
PCT/DK1994/000486 WO1995017422A1 (en) 1993-12-23 1994-12-22 Compounds with growth hormone releasing properties

Publications (2)

Publication Number Publication Date
DE69427650D1 DE69427650D1 (de) 2001-08-09
DE69427650T2 true DE69427650T2 (de) 2001-11-22

Family

ID=27439242

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69427650T Expired - Fee Related DE69427650T2 (de) 1993-12-23 1994-12-22 Verbindungen mit wachstumshormon-freisetzenden eigenschaften

Country Status (18)

Country Link
US (1) US5854211A (de)
EP (1) EP0736038B1 (de)
JP (1) JP3759748B2 (de)
CN (1) CN1052730C (de)
AT (1) ATE202785T1 (de)
AU (1) AU683121B2 (de)
CA (1) CA2179598A1 (de)
CZ (1) CZ291382B6 (de)
DE (1) DE69427650T2 (de)
FI (1) FI962591A (de)
HU (1) HU221092B1 (de)
IL (1) IL112111A (de)
NO (1) NO315611B1 (de)
PL (1) PL181286B1 (de)
RU (1) RU2167881C2 (de)
TW (1) TW438810B (de)
UA (1) UA45962C2 (de)
WO (1) WO1995017422A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995014666A1 (en) * 1993-11-24 1995-06-01 Merck & Co., Inc. Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
WO1997022004A1 (en) 1995-12-13 1997-06-19 Merck & Co., Inc. Assays for growth hormone secretagogue receptors
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
AU7906998A (en) 1997-06-20 1999-01-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
BR9906975A (pt) 1998-01-16 2000-10-17 Novo Nordisk As Composto, uso do mesmo, composição farmacêutica, e, processo para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
CA2333857A1 (en) 1998-07-13 2000-01-20 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
US6645726B1 (en) 1998-08-10 2003-11-11 Merck & Co., Inc. Canine growth hormone secretagogue receptor
EP1141014B1 (de) 1999-01-06 2004-12-08 Genentech, Inc. Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
CA2362290A1 (en) 1999-02-18 2000-08-24 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
AU5630800A (en) * 1999-06-22 2001-01-09 Arno F Spatola Antimicrobial agents
JP4644402B2 (ja) * 1999-07-26 2011-03-02 ベイラー カレッジ オブ メディスン 超高活性ブタ成長ホルモン放出ホルモン類似体
ATE343562T1 (de) * 2000-03-23 2006-11-15 Elan Pharm Inc Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
EP1282437B1 (de) 2000-05-16 2008-03-19 Genentech, Inc. Behandlung von knorpelerkrankungen
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
NZ545940A (en) 2003-09-12 2009-12-24 Tercica Inc Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EP2118080B1 (de) 2007-02-09 2016-08-31 Ocera Therapeutics, Inc. Makrocyclische ghrelin-rezeptormodulatoren und verwendungsverfahren dafür
EP2155769B1 (de) 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Schutz gegen gewebedegeneration
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
CN106572997A (zh) 2014-05-30 2017-04-19 辉瑞公司 作为选择性雄激素受体调节剂的腈衍生物
WO2016129645A1 (ja) 2015-02-10 2016-08-18 富士フイルム株式会社 光学部材、光学素子、液晶表示装置および近接眼光学部材
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803261A (en) * 1986-06-27 1989-02-07 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide
US5480869A (en) * 1990-01-09 1996-01-02 The Regents Of The University Of California Anti-inflammatory peptide analogs and treatment to inhibit vascular leakage in injured tissues
US5486505A (en) * 1990-07-24 1996-01-23 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
IL98910A0 (en) * 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5470753A (en) * 1992-09-03 1995-11-28 Selectide Corporation Peptide sequencing using mass spectrometry
SE9300012D0 (sv) * 1993-01-05 1993-01-05 Astra Ab New peptides
US5559209A (en) * 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
SK281963B6 (sk) * 1993-12-23 2001-09-11 Novo Nordisk A/S Zlúčeniny ovplyvňujúce uvoľňovanie rastového hormónu, farmaceutické prostriedky s ich obsahom a ich použitie

Also Published As

Publication number Publication date
JPH09506873A (ja) 1997-07-08
HU221092B1 (en) 2002-08-28
RU2167881C2 (ru) 2001-05-27
WO1995017422A1 (en) 1995-06-29
HUT74820A (en) 1997-02-28
NO315611B1 (no) 2003-09-29
AU683121B2 (en) 1997-10-30
IL112111A (en) 2000-07-16
CN1138334A (zh) 1996-12-18
DE69427650D1 (de) 2001-08-09
HU9601740D0 (en) 1996-08-28
NO962664L (no) 1996-08-23
PL315114A1 (en) 1996-10-14
CA2179598A1 (en) 1995-06-29
CZ291382B6 (cs) 2003-02-12
EP0736038B1 (de) 2001-07-04
ATE202785T1 (de) 2001-07-15
UA45962C2 (uk) 2002-05-15
TW438810B (en) 2001-06-07
IL112111A0 (en) 1995-03-15
EP0736038A1 (de) 1996-10-09
CZ183396A3 (en) 1997-02-12
PL181286B1 (pl) 2001-07-31
US5854211A (en) 1998-12-29
NO962664D0 (no) 1996-06-21
CN1052730C (zh) 2000-05-24
AU1310695A (en) 1995-07-10
FI962591A0 (fi) 1996-06-20
FI962591A (fi) 1996-06-20
JP3759748B2 (ja) 2006-03-29

Similar Documents

Publication Publication Date Title
DE69427650D1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
DE69941255D1 (de) Verbindungen mit wachstumshormon freisetzenden eigenschaften
ATE190352T1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
TR200100637T2 (tr) Yeni doğal ürün türevleri
ATE390124T1 (de) Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
DE60035133D1 (de) Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten
DE69943239D1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
ATE243521T1 (de) Verwendung von biopolymeren zur behandlung der muskeln
DE69314586D1 (de) Arzneimittelzusammensetzung enthaltend TCF-II
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
DK0842193T3 (da) Somatostatin-analoge cykliske peptider med hæmmende aktivitet på væksthormon
DE69919195D1 (de) Verbindungen mit wachstumshormon-freisetzender eigenschaft
MX9206339A (es) Nueva proteina inhibidora de trombina a partir de chinches de monte
NZ323207A (en) Hemoregulatory compounds
TH32887A (th) สารประกอบทางเคมี

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SAPPHIRE THERAPEUTICS, INC., BRIDGEWATER, N.J., US

8339 Ceased/non-payment of the annual fee